Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG
Grosse to take over as Group CEO on July 1, 2025
Advertisement
The Supervisory Board of Sartorius AG appointed Dr. Michael Grosse Chief Executive Officer of Sartorius. He will take over this position on July 1, 2025, from Dr. Joachim Kreuzburg, who will continue to lead the company until that time. The appointment is the result of a selection process that started in the summer of 2024, after Kreuzburg had announced that, after more than two decades as CEO, he would not seek another renewal of his contract, which expires in November 2025.
The Chairman of the Supervisory Board, Dr. Lothar Kappich, commented: ”Joachim Kreuzburg's track record after 22 years at the helm of the company is unparalleled. With his dynamic entrepreneurial personality, he has transformed Sartorius into a life science tools company and led the company amongst the top of global players of this segment. During his term of office, Sartorius’ value increased tremendously while numerous new jobs were created. Following Mr. Kreuzburg’s early notice, we were able to organize a well-structured succession process which was successfully concluded with the appointment of Mr. Grosse. Michael Grosse has impressively demonstrated his operational and strategic skills across a range of industries and business models, and his openness, persistence and focus on results are an excellent match with the Sartorius culture. I am now very much looking forward to working together with Mr. Kreuzburg and our successful Executive Board for another six months, and then to welcoming Mr. Grosse to Sartorius next July.”
Joachim Kreuzburg said: ”Sartorius is a truly unique company with an outstanding positioning and a great team. In the coming months, we will work together with all our energy to ensure that the company continues to develop more innovatively, faster, and more profitably than the competition. I am pleased that in Mr. Grosse such a convincing personality has been found as my successor.”
Michael Grosse, designated Chief Executive Officer, said: ”Sartorius is a strongly positioned company in one of the most relevant industries of the future. The company has a powerful mission, and I look very much forward to contributing to the progress in the biopharma industry with this successful team in a few months’ time.“
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

WACKER BIOSOLUTIONS under New Leadership - Susanne Leonhartsberger will leave the company at her own request at the end of 2024.

DMC Biotechnologies announces Dr. Jim Flatt as CEO - DMC seeking to transform how the world makes chemicals

Merck: New CEOs for Life Science and Healthcare business sectors and New Chief People Officer - Appointment of three internal senior executives ensures strategic continuity with a new era of leadership

CureVac appoints new CEO - Dr. Franz-Werner Haas to complete tenure as CEO by March 31, 2023

LenioBio announces new CEO - Founder will be stepping down as CEO

T-CURX announces senior leadership appointments - T-CURX completes formation of highly experienced clinical team to rapidly advance clinical translation of its next-generation CAR-T cell therapies

Samanta Cimitan Appointed Chief Executive Officer (CEO) at Celonic

BioGaia appoints Theresa Agnew as new CEO

EVIDENT Corporation Appoints New CEO and COO

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

Biotage AB appointment of new CEO
